Staphylococcus epidermidis is one of the most common bacteria living on human skin, and for most people it’s completely harmless. It becomes a problem almost exclusively when it gets inside the body through medical devices like catheters, artificial joints, or heart valves. Once there, it can cause a range of infections, from bloodstream infections to heart valve inflammation to joint infections around implants.
A Normal Skin Resident That Turns Opportunistic
Your skin is home to roughly a thousand species of bacteria, and S. epidermidis is one of the most abundant. Under normal conditions, it actually helps protect you. NIH research has shown that S. epidermidis breaks down a fat molecule called sphingomyelin on skin cells, producing ceramides that reduce water loss through the skin’s outer layer. This relationship benefits both sides: the bacteria get nutrients they need to survive in the salty environment of the skin surface, and your skin barrier stays healthier in return.
The trouble starts when S. epidermidis crosses from the skin’s surface into the body, which almost always happens through a break created by a medical procedure. A catheter insertion, a joint replacement surgery, or a heart valve implant all create pathways for this otherwise peaceful bacterium to reach places it doesn’t belong.
How It Takes Hold on Medical Devices
What makes S. epidermidis particularly problematic in hospitals is its ability to form biofilms, sticky layers of bacteria that coat surfaces. The process happens in stages. First, individual bacteria latch onto the surface of an implanted device. As soon as any foreign material enters the body, it gets coated with proteins from the blood and surrounding tissue, including fibronectin, fibrinogen, and collagen. S. epidermidis carries surface proteins that bind directly to these host proteins, giving it a strong initial grip.
Once attached, the bacteria begin building upward, creating a three-dimensional structure where most cells aren’t even touching the device surface anymore. They’re embedded in a self-produced matrix of sugars that acts like a protective shield. This biofilm makes the bacteria far harder for the immune system to clear and far less susceptible to antibiotics. Eventually, pieces of the biofilm can break off, releasing bacteria to colonize new sites or enter the bloodstream.
Catheter-Related Bloodstream Infections
S. epidermidis and related coagulase-negative staphylococci are one of the leading causes of bloodstream infections tied to intravenous catheters. These are central lines placed in large veins for delivering medications, fluids, or nutrition over extended periods. Because the catheter sits in the bloodstream for days or weeks, biofilm-forming bacteria on the skin around the insertion site can migrate along the catheter and into the blood. Symptoms typically include fever without an obvious source. Removing the catheter is often a necessary part of treatment, since antibiotics alone may not penetrate the biofilm coating the device.
Heart Valve Infections
S. epidermidis is one of the most common causes of infective endocarditis, an infection of the heart’s inner lining and valves. It affects both natural and prosthetic (replacement) heart valves, though it’s especially significant in people with prosthetic valves.
For prosthetic valve infections that develop within two months of surgery, S. epidermidis is a primary culprit, typically introduced during the operation itself. But it also causes later-onset infections, sometimes appearing months after surgery from transient episodes of bacteria entering the blood. These later infections tend to progress slowly, over weeks to months, and may not have an obvious point of entry. Symptoms can include persistent fever, new or changing heart murmurs, fatigue, and small red spots on the skin called petechiae. Diagnosis usually requires blood cultures and imaging of the heart valves.
Prosthetic Joint and Implant Infections
Joint replacements (hip, knee, shoulder) are another common target. S. epidermidis can colonize the surface of the artificial joint during or after surgery. People with a prosthetic joint infection typically notice increasing pain around the implant site, and there may be visible swelling or drainage of pus near the surgical wound. These infections can be slow to develop, sometimes surfacing months after the original procedure.
Brain shunts, devices placed to drain excess fluid from around the brain, are also vulnerable. Shunt infections caused by S. epidermidis can be sneaky. Some people have no symptoms at all, while others develop headaches, dizziness, nausea, vomiting, or confusion. Cardiac devices like pacemakers and defibrillators carry similar risks, since the leads and hardware provide surfaces for biofilm formation.
Neonatal Infections in Premature Infants
S. epidermidis has emerged as the leading cause of late-onset sepsis (bloodstream infection developing after the first few days of life) in very low birth weight preterm infants. In one study, S. epidermidis was identified in 71% of sepsis episodes among preterm neonates in intensive care, affecting about 19% of infants in the unit. Several factors converge to make NICUs a high-risk environment: premature babies have underdeveloped immune systems, they’re exposed to catheters, feeding tubes, and ventilators that provide surfaces for biofilm growth, and widespread antibiotic use creates selective pressure favoring resistant strains.
The consequences go beyond the infection itself. S. epidermidis sepsis in preterm infants has been linked to complications including chronic lung disease, brain white matter injury, gut inflammation, and eye problems affecting vision. These effects can have lasting developmental consequences, which is why neonatal S. epidermidis infections, though sometimes dismissed as minor, are taken increasingly seriously.
Why It’s Hard to Treat
A major challenge with S. epidermidis is antibiotic resistance. Much like its more famous relative MRSA (methicillin-resistant Staphylococcus aureus), S. epidermidis frequently carries resistance to methicillin and related antibiotics. Studies have found that roughly 60 to 70% of S. epidermidis strains isolated from clinical infections are methicillin-resistant, a rate that has remained stubbornly high. This limits treatment options considerably.
Biofilm formation compounds the resistance problem. Bacteria embedded in a biofilm can tolerate antibiotic concentrations hundreds of times higher than what would kill them in their free-floating state. For this reason, treatment of device-related S. epidermidis infections often requires removing the infected device entirely, whether it’s a catheter, a prosthetic joint, or a heart valve. Antibiotics alone frequently fail when the biofilm remains intact on an implanted surface.
How It Differs From Staph Aureus
S. epidermidis is sometimes confused with Staphylococcus aureus, its more aggressive relative, but the two behave quite differently. S. aureus produces an enzyme called coagulase that clots blood plasma. S. epidermidis does not, which is why it’s classified as a “coagulase-negative” staphylococcus. In the lab, this single test is the primary way the two are distinguished.
S. aureus also tends to cause more overtly destructive infections: skin abscesses, pneumonia, bone infections, and rapidly progressing bloodstream infections in otherwise healthy people. S. epidermidis rarely causes disease in people without implanted devices or compromised immune systems. It’s a quieter pathogen, one that exploits medical technology rather than overwhelming healthy tissue. Its colonies typically appear white on culture plates, compared to the golden pigment that gives S. aureus (“aureus” meaning gold) its name, and it doesn’t produce the toxins responsible for many of the tissue-damaging effects of S. aureus infections.